110 related articles for article (PubMed ID: 10802698)
21. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
Odoux C; Albers A
Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187
[TBL] [Abstract][Full Text] [Related]
22. License to kill tumors: how much hope is justified for trail?
Frank S; Ebert AD
Curr Pharm Des; 2001 Nov; 7(16):1689-701. PubMed ID: 11562306
[TBL] [Abstract][Full Text] [Related]
23. [Clinical applications of TRAIL in cancers. The prostate cancer example].
Hesry V; Guillaudeux T; Patard JJ
Pathol Biol (Paris); 2003 Apr; 51(3):123-8. PubMed ID: 12781791
[No Abstract] [Full Text] [Related]
24. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis.
Kim JH; Ajaz M; Lokshin A; Lee YJ
Clin Cancer Res; 2003 Aug; 9(8):3134-41. PubMed ID: 12912965
[TBL] [Abstract][Full Text] [Related]
25. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.
Cretney E; Shanker A; Yagita H; Smyth MJ; Sayers TJ
Immunol Cell Biol; 2006 Feb; 84(1):87-98. PubMed ID: 16405656
[TBL] [Abstract][Full Text] [Related]
26. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
27. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice.
Hao C; Song JH; Hsi B; Lewis J; Song DK; Petruk KC; Tyrrell DL; Kneteman NM
Cancer Res; 2004 Dec; 64(23):8502-6. PubMed ID: 15574753
[TBL] [Abstract][Full Text] [Related]
28. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
Kontny HU; Hämmerle K; Klein R; Shayan P; Mackall CL; Niemeyer CM
Cell Death Differ; 2001 May; 8(5):506-14. PubMed ID: 11423911
[TBL] [Abstract][Full Text] [Related]
30. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
31. TRAIL and chemotherapeutic drugs in cancer therapy.
Wu XX; Ogawa O; Kakehi Y
Vitam Horm; 2004; 67():365-83. PubMed ID: 15110186
[TBL] [Abstract][Full Text] [Related]
32. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.
Ozoren N; Kim K; Burns TF; Dicker DT; Moscioni AD; El-Deiry WS
Cancer Res; 2000 Nov; 60(22):6259-65. PubMed ID: 11103780
[TBL] [Abstract][Full Text] [Related]
33. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity.
Higuchi H; Bronk SF; Taniai M; Canbay A; Gores GJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):461-7. PubMed ID: 12388624
[TBL] [Abstract][Full Text] [Related]
34. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice.
Shankar S; Singh TR; Chen X; Thakkar H; Firnin J; Srivastava RK
Int J Oncol; 2004 May; 24(5):1133-40. PubMed ID: 15067334
[TBL] [Abstract][Full Text] [Related]
35. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis.
Marini P; Schmid A; Jendrossek V; Faltin H; Daniel PT; Budach W; Belka C
BMC Cancer; 2005 Jan; 5():5. PubMed ID: 15651986
[TBL] [Abstract][Full Text] [Related]
36. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis.
Martin JH; Potthoff A; Ledig S; Cornberg M; Jandl O; Manns MP; Kubicka S; Flemming P; Athmann C; Beil W; Wagner S
Helicobacter; 2004 Oct; 9(5):371-86. PubMed ID: 15361075
[TBL] [Abstract][Full Text] [Related]
37. Intracellular mechanisms of TRAIL and its role in cancer therapy.
Srivastava RK
Mol Cell Biol Res Commun; 2000 Aug; 4(2):67-75. PubMed ID: 11170835
[No Abstract] [Full Text] [Related]
38. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5).
Jung EM; Lim JH; Lee TJ; Park JW; Choi KS; Kwon TK
Carcinogenesis; 2005 Nov; 26(11):1905-13. PubMed ID: 15987718
[TBL] [Abstract][Full Text] [Related]
39. Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand.
Qin JZ; Bacon P; Chaturvedi V; Nickoloff BJ
J Invest Dermatol; 2001 Oct; 117(4):898-907. PubMed ID: 11676830
[TBL] [Abstract][Full Text] [Related]
40. Involvement of TRAIL and its receptors in viral hepatitis.
Mundt B; Kühnel F; Zender L; Paul Y; Tillmann H; Trautwein C; Manns MP; Kubicka S
FASEB J; 2003 Jan; 17(1):94-6. PubMed ID: 12475902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]